MYGN FY 2024 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

FY 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$838M+11.2% YoY

Gross Profit

$585M69.9% margin

Operating Income

-$124M-14.7% margin

Net Income

-$127M-15.2% margin

EPS (Diluted)

$-1.41

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$38M

Stock-Based Comp.

$50M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$327M

Stockholders' Equity

$701M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$838M	$753M	+11.2%
Gross Profit	$585M	$517M	+13.2%
Operating Income	-$124M	-$257M	+52.0%
Net Income	-$127M	-$263M	+51.7%